PDGFRB and adrenal cortex carcinoma: A phase II study testing imatinib in patients with metastatic solid tumors expressing PDGFR or c-KIT included 4 patients with metastatic ACC, but none of those patients showed clinical response to therapy.[71] On the other hand, another study exploring the combination of imatinib with dacarbazine and capecitabine, in patients with advanced endocrine malignancies documented tumor responses in 2 out of 7 patients with metastatic ACC.[72]